FDA Tentative Approval for Perrigo Epiduo

FDA has granted Perrigo tentative ANDA approval for a generic version of Gladerma’s Epiduo Gel (adapalene and benzoyl peroxide 0.1%/2.5%), indicated for treating acne vulgaris in patients 12 years of age and older. Annual sales for the brand product are about $379 million. According to FDA’s Orange Book, there are several patents expiring in 2027.

Read more